ME02499B - Anti-il- 23-antitijela - Google Patents
Anti-il- 23-antitijelaInfo
- Publication number
- ME02499B ME02499B MEP-2016-176A MEP2016176A ME02499B ME 02499 B ME02499 B ME 02499B ME P2016176 A MEP2016176 A ME P2016176A ME 02499 B ME02499 B ME 02499B
- Authority
- ME
- Montenegro
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- antigen
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 47
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 25
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
Claims (26)
1. Humanizovano anti-IL-23p19 antitelo ili njegov antigen-vezujući fragment,pri čemu antitelo ili njegov antigen-vezujući fragment obuhvata: a) varijabilnu regiju lakog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO:19 (CDR1-L); sekvencu aminokiseline SEQ ID NO:20 (CDR2-L); i sekvencu aminokiseline SEQ ID NO:21 (CDR3-L); ib) varijabilnu regiju teškog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO: 66 ili 67 (CDR1-H); sekvencu aminokiseline SEQ ID NO:64 (CDR2-H); i sekvencu aminokiseline SEQ ID NO:65 (CDR3-H).
2.Humanizovano anti-IL-23p19 antitelo ili njegov antigen-vezujući fragment prema zahtevu 1, pri čemu antitelo ili njegov antigen-vezujući fragment obuhvata: a) varijabilnu regiju lakog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO:19 (CDR1-L); sekvencu aminokiseline SEQ ID NO:20 (CDR2-L); i sekvencu aminokiseline SEQ ID NO:21 (CDR3-L); i b) varijabilnu regiju teškog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO:66 (CDR1-H); sekvencu aminokiseline SEQ ID NO:64 (CDR2-H); i sekvencu aminokiseline SEQ ID NO:65 (CDR3-H).
3. Humanizovano anti-IL-23p19 antitelo ili njegov antigen-vezujući fragment prema zahtevu 1, pri čemu antitelo ili njegov antigen-vezujući fragment obuhvata: a) varijabilnu regiju lakog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO:19 (CDR1-L); sekvencu aminokiseline SEQ ID NO:20 (CDR2-L); i sekvencu aminokiseline SEQ ID NO:21 (CDR3-L); i b) varijabilnu regiju teškog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO:67 (CDR1-H); sekvencu aminokiseline SEQ ID NO:64 (CDR2-H); i sekvencu aminokiseline SEQ ID NO:65 (CDR3-H).
4. Humanizovano anti-IL-23p19 antitelo ili njegov antigen-vezujući fragment prema zahtevu 1, pri čemu antitelo ili njegov antigen-vezujući fragment obuhvata varijabilnu regiju lakog lanca koja obuhvata sekvencu aminokiseline bilo koju od SEQ ID NO:158, 160, 162 ili 164; i varijabilnu regiju teškog lanca koja obuhvata sekvencu aminokiseline bilo koju od SEQ ID NO:166 ili 168.
5. Humanizovano anti-IL-23p19 antitelo ili njegov antigen-vezujući fragment prema zahtevu 4, pri čemu antitelo ili njegov antigen-vezujući fragment obuhvata varijabilnu regiju lakog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO:160 i varijabilnu regiju teškog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO:166.
6. Humanizovano anti-IL-23p19 antitelo ili njegov antigen-vezujući fragment prema zahtevu 4, pri čemu antitelo ili njegov antigen-vezujući fragment obuhvata varijabilnu regiju lakog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO:160 i varijabilnu regiju teškog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO:168.
7. Humanizovano anti-IL-23p19 antitelo ili njegov antigen-vezujući fragment prema zahtevu 4, pri čemu antitelo ili njegov antigen-vezujući fragment obuhvata varijabilnu regiju lakog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO:158 i varijabilnu regiju teškog lanca koja obuhvata sekvencu aminokiseline SEQ ID NO:166.
8.Humanizovano anti-IL-23p19 antitelo ili njegov antigen-vezujući fragment prema zahtevu 4, pri čemu antitelo ili njegov antigen-vezujući fragment obuhvata sekvencu aminokiseline SEQ ID NO:166 ili 168 vezanu za humanu IgG1 konstantnu regiju teškog lanca; i sekvencu aminokiseline SEQ ID NO:158 ili 160 vezanu za humanu kapa konstantnu regiju lakog lanca.
9.Humanizovano anti-IL-23p19 antitelo ili njegov antigen-vezujući fragment prema zahtevu 1, pri čemu antitelo ili njegov antigen-vezujući fragment obuhvata: a) humanizovani varijabilni domen lakog lanca koji obuhvata CDR-ove SEQ ID NO:158 ili 160 i okvirne regije koje imaju sekvencu aminokiseline koja je najmanje 90% identična sekvenci aminokiseline okvirne regije varijabilnog domena lakog lanca sekvence aminokiseline SEQ ID NO:158 ili 160; i b) humanizovani varijabilni domen teškog lanca koji obuhvata CDR-ove SEQ ID NO:166 ili 168 i okvirne regije koje imaju sekvencu aminokiseline koja je najmanje 90% identična sekvenci aminokiseline okvirne regije varijabilnog domena teškog lanca sekvence aminokiseline SEQ ID NO:166 ili 168.
10.Humanizovano anti-IL-23p19 antitelo prema bilo kom od zahteva 1 do 9, pri čemu je pomenuto antitelo monoklonsko antitelo.
11.Humanizovano anti-IL-23p19 antitelo prema zahtevu 1, pri čemu je antitelo humanizovano monoklonsko anti-IL-23p19 antitelo koje obuhvata laki lanac koji obuhvata sekvencu aminokiseline SEQ ID NO:174 ili 180 i težak lanac koji obuhvata sekvencu aminokiseline SEQ ID NO:176 ili 178.
12. Humanizovano monoklonsko anti-IL-23p19 antitelo prema zahtevu 11, pri čemu pomenuto antitelo obuhvata laki lanac koji obuhvata sekvencu aminokiseline SEQ ID NO:174 i težak lanac koji obuhvata sekvencu aminokiseline SEQ ID NO:176.
13.Humanizovano monoklonsko anti-IL-23p19 antitelo prema zahtevu 11, pri čemu pomenuto antitelo obuhvata laki lanac koji obuhvata sekvencu aminokiseline SEQ ID NO:174 i težak lanac koji obuhvata sekvencu aminokiseline SEQ ID NO:178.
14.Humanizovano monoklonsko anti-IL-23p19 antitelo prema zahtevu 11, pri čemu pomenuto antitelo obuhvata laki lanac koji obuhvata sekvencu aminokiseline SEQ ID NO:180 i težak lanac koji obuhvata sekvencu aminokiseline SEQ ID NO:176.
15.Antitelo ili antigen-vezujući fragment prema bilo kom od zahteva 1 do 14 za upotrebu u medicini.
16.Antitelo ili antigen-vezujući fragment prema zahtevu 15, pri čemu se koristi za tretiranje zapaljenske bolesti, autoimune bolesti, respiratorne bolesti, metaboličkog poremećaja ili kancera.
17.Antitelo ili antigen-vezujući fragment prema zahtevu 16, pri čemu se koristi za tretiranje psorijaze, zapaljenske bolesti creva, psorijaznog artritisa, multipla skleroze, reumatoidnog artritisa, Kronove bolesti, ulceroznog kolitisa ili ankilozirajućeg spondilitisa.
18.Antitelo ili antigen-vezujući fragment prema zahtevu 16, pri čemu se koristi za tretiranje astme ili HOBP (hronične opstruktivne bolesti pluća).
19.Farmaceutska kompozicija koja obuhvata antitelo ili antigen-vezujući fragment prema bilo kom od zahteva 1 do 14 i farmaceutski prihvatljivi nosač.
20.Izolovani polinukleotid koji obuhvata sekvencu koja kodira varijabilnu regiju lakog lanca antitela ili fragmenta antitela koja ima sekvencu aminokiseline SEQ ID NO:158, 160, 162 ili 164, i koja kodira varijabilnu regiju teškog lanca antitela ili fragmenta antitela koja ima sekvencu aminokiseline SEQ ID NO: 166 ili 168.
21.Izolovani polinukleotid prema zahtevu 20, pri čemu pomenuti polinukleotid obuhvata sekvencu koja kodira laki lanac antitela koji ima sekvencu aminokiseline SEQ ID NO:174 ili 180, i koja kodira težak lanac antitela koji ima sekvencu aminokiseline SEQ ID NO:176 ili 178.
22.Ekspresioni vektor koji obuhvata polinukleotid prema zahtevu 20 ili 21.
23.Ćelija domaćina koja obuhvata: a) izolovani polinukleotid koji obuhvata sekvencu koja kodira varijabilnu regiju lakog lanca antitela ili fragmenta antitela koja ima sekvencu aminokiseline SEQ ID NO:158, 160, 162 ili 164; i b) izolovani polinukleotid koji obuhvata sekvencu koja kodira varijabilnu regiju teškog lanca antitela ili fragmenta antitela koja ima sekvencu aminokiseline SEQ ID NO: 166 ili 168.
24.Ćelija domaćina koja obuhvata: a) izolovani polinukleotid koji obuhvata sekvencu koja kodira laki lanac antitela koji ima sekvencu aminokiseline SEQ ID NO:174 ili 180; i b) izolovani polinukleotid koji obuhvata sekvencu koja kodira težak lanac antitela koji ima sekvencu aminokiseline SEQ ID NO:176 ili 178.
25.Postupak proizvodnje antitela ili antigen-vezujućeg fragmenta koji obuhvata: a) dobijanje ćelije domaćina prema zahtevu 23 ili 24; i b) kultivisanje ćelije domaćina.
26.Postupak prema zahtevu 25, koji dalje obuhvata izolovanje i prečišćavanje antitela ili antigen-vezujućeg fragmenta.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41015810P | 2010-11-04 | 2010-11-04 | |
| US41195310P | 2010-11-10 | 2010-11-10 | |
| US41259410P | 2010-11-11 | 2010-11-11 | |
| US201161448785P | 2011-03-03 | 2011-03-03 | |
| EP11781949.0A EP2635601B1 (en) | 2010-11-04 | 2011-11-02 | Anti-il-23 antibodies |
| PCT/US2011/058869 WO2012061448A1 (en) | 2010-11-04 | 2011-11-02 | Anti-il-23 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02499B true ME02499B (me) | 2017-02-20 |
Family
ID=44936573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-176A ME02499B (me) | 2010-11-04 | 2012-11-02 | Anti-il- 23-antitijela |
Country Status (39)
| Country | Link |
|---|---|
| US (6) | US8778346B2 (me) |
| EP (4) | EP3115375A1 (me) |
| JP (3) | JP6126532B2 (me) |
| KR (2) | KR102049223B1 (me) |
| CN (2) | CN103282382B (me) |
| AP (1) | AP3953A (me) |
| AR (1) | AR083747A1 (me) |
| AU (3) | AU2011323426B2 (me) |
| BR (1) | BR112013011065B1 (me) |
| CA (2) | CA2816950C (me) |
| CO (1) | CO6801628A2 (me) |
| CY (2) | CY1118014T1 (me) |
| DK (1) | DK2635601T3 (me) |
| EA (2) | EA201890548A1 (me) |
| EC (1) | ECSP13012649A (me) |
| ES (1) | ES2593754T3 (me) |
| GE (1) | GEP201706733B (me) |
| HR (1) | HRP20161141T1 (me) |
| HU (2) | HUE030916T2 (me) |
| IL (2) | IL225648A (me) |
| LT (2) | LT2635601T (me) |
| LU (1) | LUC00132I2 (me) |
| MA (1) | MA34641B1 (me) |
| ME (1) | ME02499B (me) |
| MX (3) | MX362039B (me) |
| MY (1) | MY162791A (me) |
| NL (1) | NL301013I2 (me) |
| NO (1) | NO2019038I1 (me) |
| NZ (1) | NZ610592A (me) |
| PE (1) | PE20141162A1 (me) |
| PH (1) | PH12013500810B1 (me) |
| PL (1) | PL2635601T3 (me) |
| PT (1) | PT2635601T (me) |
| RS (1) | RS55161B1 (me) |
| SG (2) | SG190006A1 (me) |
| SI (1) | SI2635601T1 (me) |
| TW (2) | TWI653242B (me) |
| UY (1) | UY33703A (me) |
| WO (1) | WO2012061448A1 (me) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| WO2012061448A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
| US11078265B2 (en) * | 2012-05-03 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Anti-IL-23 antibodies |
| TWI636063B (zh) * | 2013-03-08 | 2018-09-21 | 美國禮來大藥廠 | 結合ｉｌ－２３之抗體 |
| HK1219425A1 (zh) | 2013-03-15 | 2017-04-07 | Amgen Inc. | 使用抗il-23抗体治疗银屑病的方法 |
| AU2014228553B2 (en) | 2013-03-15 | 2019-01-24 | Amgen Inc. | Methods for treating Crohn's disease using an anti-IL23 antibody |
| WO2016014775A1 (en) | 2014-07-24 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of il-23a related diseases |
| WO2016036918A1 (en) * | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| BR112017014684A2 (en) * | 2015-02-04 | 2018-01-09 | Boehringer Ingelheim International Gmbh | methods of treatment of inflammatory diseases |
| EP3685856A1 (en) | 2015-04-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Treatment of asthma with anti-il-23a antibodies |
| KR102644875B1 (ko) | 2015-07-23 | 2024-03-06 | 베링거잉겔하임인터내쇼날유한회사 | Il-23a 및 b-세포 활성화 인자(baff)를 표적화하는 화합물 및 이의 용도 |
| CN108290058B (zh) * | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| TWI733695B (zh) * | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
| SI3370768T1 (sl) | 2015-11-03 | 2022-04-29 | Janssen Biotech, Inc. | Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe |
| JP2019508370A (ja) | 2015-12-22 | 2019-03-28 | アムジェン インコーポレイテッド | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
| WO2017180821A1 (en) | 2016-04-15 | 2017-10-19 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| EP3526252A2 (en) | 2016-10-14 | 2019-08-21 | Boehringer Ingelheim International GmbH | Methods of treating diseases with il-23a antibody |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| KR20200118117A (ko) * | 2018-02-05 | 2020-10-14 | 테사로, 인코포레이티드 | 소아용 니라파립 제제 및 소아용 치료 방법 |
| TWI837532B (zh) * | 2018-03-30 | 2024-04-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
| EA202190197A1 (ru) | 2018-07-13 | 2021-04-26 | Астразенека Коллаборэйшн Венчерз, Ллс | Лечение язвенного колита с помощью бразикумаба |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CN109810947B (zh) * | 2019-01-18 | 2021-06-11 | 北京贝来生物科技有限公司 | 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用 |
| PH12021552536A1 (en) * | 2019-04-15 | 2022-07-04 | Sun Pharmaceutical Ind Ltd | Methods for treatment of subjects with psoriatic arthritis |
| US20210070852A1 (en) * | 2019-09-09 | 2021-03-11 | Boehringer Ingelheim International Gmbh | Anti-IL-23p19 Antibody Formulations |
| KR20220143005A (ko) * | 2019-12-20 | 2022-10-24 | 노바록 바이오테라퓨틱스 리미티드 | 항-인터루킨-23 p19 항체 및 이의 사용 방법 |
| CN111956606B (zh) * | 2020-08-31 | 2021-05-14 | 江苏荃信生物医药有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂 |
| TW202428304A (zh) | 2020-09-10 | 2024-07-16 | 美商美國禮來大藥廠 | 治療性抗體調配物 |
| UY39467A (es) * | 2020-10-13 | 2022-04-29 | Janssen Biotech Inc | Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii |
| JP2024521748A (ja) | 2021-05-28 | 2024-06-04 | イーライ リリー アンド カンパニー | 潰瘍性大腸炎に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体調節 |
| KR102761841B1 (ko) | 2021-07-09 | 2025-02-05 | 연세대학교 산학협력단 | Il-23에 의해 매개되는 질환의 중증도 예측용 조성물 |
| EP4409298A1 (en) | 2021-09-30 | 2024-08-07 | Eli Lilly and Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
| WO2024077113A1 (en) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Methods of treating fatigue in ulcerative colitis |
| IL319239A (en) | 2022-10-21 | 2025-04-01 | Chong Kun Dang Pharmaceutical Corp | Stable antibody preparation |
| AU2024224464A1 (en) | 2023-02-22 | 2025-08-14 | Eli Lilly And Company | Regulation of genes in ulcerative colitis and the uses thereof |
| WO2024263900A2 (en) * | 2023-06-22 | 2024-12-26 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
| WO2025117506A1 (en) | 2023-11-29 | 2025-06-05 | Gilead Sciences, Inc. | Therapies for the treatment of inflammatory bowel disease |
| WO2025170982A2 (en) * | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2025171006A1 (en) * | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 binding protein compositions and methods of use |
| CN117875575B (zh) * | 2024-03-12 | 2024-05-28 | 中国电子科技集团公司第二十九研究所 | 一种基于混合仿生算法的干扰资源分配方法 |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0656789B1 (en) | 1992-08-21 | 1997-12-17 | Genentech, Inc. | Method for treating a lfa-1-mediated disorder |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
| AU2661199A (en) | 1998-02-06 | 1999-08-23 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
| EP1072610B1 (en) | 1998-04-14 | 2010-07-21 | Chugai Seiyaku Kabushiki Kaisha | Novel cytokine-like protein |
| IL148300A0 (en) | 1999-09-09 | 2002-09-12 | Schering Corp | Mammalian cytokines; related reagents and methods |
| US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| EP1287130B2 (en) | 2000-05-10 | 2017-07-26 | Merck Sharp & Dohme Corp. | Mammalian cytokine receptor subunit proteins, related reagents and methods |
| US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| WO2003034818A1 (en) | 2001-10-24 | 2003-05-01 | Chugai Seiyaku Kabushiki Kaisha | Sgrf genetically modified nonhuman animal |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| DK1576011T3 (da) | 2002-10-30 | 2009-11-30 | Genentech Inc | Inhibering af IL-17 produktion |
| WO2004058178A2 (en) | 2002-12-23 | 2004-07-15 | Schering Corporation | Uses of mammalian cytokine; related reagents |
| US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| SI1601694T1 (sl) | 2003-03-10 | 2010-01-29 | Schering Corp | Uporabe IL-23 antagonistov; sorodni reagenti |
| US7413894B2 (en) | 2003-07-01 | 2008-08-19 | University Of Virginia Patent Foundation | TAG-1 and TAG-2 proteins and uses thereof |
| RS53073B (sr) | 2003-11-04 | 2014-04-30 | Novartis Vaccines And Diagnostics Inc. | Upotreba antagonističkih anti-cd40 monoklonska antitela |
| DK1684805T3 (da) | 2003-11-04 | 2010-10-04 | Novartis Vaccines & Diagnostic | Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| JP4903061B2 (ja) | 2004-02-17 | 2012-03-21 | シェーリング コーポレイション | Ｉｌ−２３活性を調節する方法；関連する試薬 |
| BRPI0510617A (pt) | 2004-05-03 | 2007-10-30 | Schering Corp | uso de expressão de il-17 para prever inflamação de pele; processos de tratamento |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| CA2581505A1 (en) * | 2004-09-27 | 2006-04-06 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006068987A2 (en) | 2004-12-20 | 2006-06-29 | Schering Corporation | Uses of il-23 antagonists in the treatment of diabetes mellitus |
| PT1896073E (pt) * | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Composições, métodos e aplicações de anticorpos anti-il-23 |
| US20090142855A1 (en) | 2005-06-30 | 2009-06-04 | Wei Tang | Polynucleotides and Polypeptides of the IL-12 Family of Cytokines |
| EA013506B1 (ru) * | 2005-08-25 | 2010-06-30 | Эли Лилли Энд Компани | Антитело к il-23 и его применение |
| CN101248088A (zh) * | 2005-08-25 | 2008-08-20 | 伊莱利利公司 | 抗il-23抗体 |
| EP2354160A1 (en) * | 2005-08-31 | 2011-08-10 | Schering Corporation | Engineered anti-IL-23-antibodies |
| CN101296706B (zh) | 2005-09-01 | 2011-11-30 | 先灵公司 | Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途 |
| US20090270480A1 (en) | 2005-12-28 | 2009-10-29 | Bernard Amegadzie | Markers and Methods for Assessing and Treating Psoriasis and Related Disorders |
| AU2006330411B2 (en) | 2005-12-29 | 2012-07-12 | Janssen Biotech, Inc. | Human anti-IL-23 antibodies, compositions, methods and uses |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| AU2007261019A1 (en) | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating IL-22 and IL-17 |
| CN101600457B (zh) | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| US20080200655A1 (en) | 2007-02-16 | 2008-08-21 | Wyeth | Protein Formulations Containing Sorbitol |
| MX2009009079A (es) | 2007-02-23 | 2009-08-31 | Schering Corp | Anticuerpos anti-il-23p19 de ingenieria. |
| CA2678863A1 (en) * | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| EP2417974A1 (en) | 2007-02-28 | 2012-02-15 | Schering Corporation | Combination therapy for treatment of immune disorders |
| PT2197903E (pt) | 2007-09-04 | 2015-01-02 | Us Gov Health & Human Serv | Delecções no domínio ii da exotoxina a de pseudomonas que reduzem toxicidade não específica |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| CA2703333A1 (en) | 2007-10-26 | 2009-04-30 | Galderma Research & Development | Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof |
| CA2607771A1 (en) | 2007-11-01 | 2009-05-01 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence | Humanized anti-venezuelan equine encephalitis virus recombinant antibody |
| TWI661833B (zh) | 2007-11-30 | 2019-06-11 | 百慕達商艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| US8563697B2 (en) | 2008-08-14 | 2013-10-22 | Cephalon Australia Pty. Ltd. | Anti-IL-12/IL-23 antibodies |
| CN102202655B (zh) | 2008-08-27 | 2013-06-19 | 默沙东公司 | 基因工程抗IL-23p19抗体的冻干制剂 |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| EP2414393A1 (en) | 2009-04-01 | 2012-02-08 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| WO2010115092A2 (en) | 2009-04-02 | 2010-10-07 | The Johns Hopkins University | Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer |
| WO2011011797A2 (en) | 2009-07-24 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cytokine compositions and methods of use thereof |
| WO2011066371A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antibodies to il-6 and use thereof |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| US8257397B2 (en) | 2009-12-02 | 2012-09-04 | Spartek Medical, Inc. | Low profile spinal prosthesis incorporating a bone anchor having a deflectable post and a compound spinal rod |
| GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
| BR112012019881A2 (pt) | 2010-02-18 | 2017-06-27 | Bristol Myers Squibb Co | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 |
| WO2011104381A2 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
| RU2626512C2 (ru) | 2010-03-01 | 2017-07-28 | Цитодин, Инк. | Концентрированные белковые фармацевтические составы и их применение |
| WO2011159750A1 (en) | 2010-06-15 | 2011-12-22 | Celgene Corporation | Biomarkers for the treatment of psoriasis |
| US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
| MX341309B (es) | 2010-07-20 | 2016-08-12 | Cephalon Australia Pty Ltd | Anticuerpos especificos del heterodimero de anti-il-23. |
| EP2640745B1 (en) | 2010-09-10 | 2018-11-07 | MedImmune Limited | Bivalent and bispecific anti-il6/anti-il23 antibodies |
| WO2012061448A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
| GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| TW201309330A (zh) | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
| WO2012104402A1 (en) | 2011-02-04 | 2012-08-09 | Ab Science | Treatment of severe persitent asthma with masitinib |
| US11078265B2 (en) | 2012-05-03 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Anti-IL-23 antibodies |
| US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
| AU2014228553B2 (en) | 2013-03-15 | 2019-01-24 | Amgen Inc. | Methods for treating Crohn's disease using an anti-IL23 antibody |
| HK1219425A1 (zh) | 2013-03-15 | 2017-04-07 | Amgen Inc. | 使用抗il-23抗体治疗银屑病的方法 |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| WO2016036918A1 (en) | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| BR112017014684A2 (en) | 2015-02-04 | 2018-01-09 | Boehringer Ingelheim International Gmbh | methods of treatment of inflammatory diseases |
| KR102644875B1 (ko) | 2015-07-23 | 2024-03-06 | 베링거잉겔하임인터내쇼날유한회사 | Il-23a 및 b-세포 활성화 인자(baff)를 표적화하는 화합물 및 이의 용도 |
| TWI733695B (zh) | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
-
2011
- 2011-11-02 WO PCT/US2011/058869 patent/WO2012061448A1/en not_active Ceased
- 2011-11-02 PT PT117819490T patent/PT2635601T/pt unknown
- 2011-11-02 EP EP16178404.6A patent/EP3115375A1/en not_active Withdrawn
- 2011-11-02 EA EA201890548A patent/EA201890548A1/ru unknown
- 2011-11-02 US US13/287,208 patent/US8778346B2/en active Active
- 2011-11-02 CA CA2816950A patent/CA2816950C/en active Active
- 2011-11-02 AP AP2013006820A patent/AP3953A/en active
- 2011-11-02 CN CN201180064083.5A patent/CN103282382B/zh active Active
- 2011-11-02 MX MX2016015419A patent/MX362039B/es unknown
- 2011-11-02 ES ES11781949.0T patent/ES2593754T3/es active Active
- 2011-11-02 SI SI201130958A patent/SI2635601T1/sl unknown
- 2011-11-02 JP JP2013537771A patent/JP6126532B2/ja active Active
- 2011-11-02 BR BR112013011065-1A patent/BR112013011065B1/pt active IP Right Grant
- 2011-11-02 AU AU2011323426A patent/AU2011323426B2/en active Active
- 2011-11-02 EP EP17179739.2A patent/EP3281954A1/en not_active Withdrawn
- 2011-11-02 NZ NZ610592A patent/NZ610592A/en unknown
- 2011-11-02 CA CA3017116A patent/CA3017116A1/en not_active Abandoned
- 2011-11-02 MX MX2019000046A patent/MX2019000046A/es unknown
- 2011-11-02 MY MYPI2013001519A patent/MY162791A/en unknown
- 2011-11-02 PH PH1/2013/500810A patent/PH12013500810B1/en unknown
- 2011-11-02 EP EP18188208.5A patent/EP3456740A1/en not_active Withdrawn
- 2011-11-02 RS RS20160762A patent/RS55161B1/sr unknown
- 2011-11-02 DK DK11781949.0T patent/DK2635601T3/en active
- 2011-11-02 CN CN201710917166.3A patent/CN107522784B/zh active Active
- 2011-11-02 MX MX2013005015A patent/MX343858B/es active IP Right Grant
- 2011-11-02 PE PE2013000951A patent/PE20141162A1/es active IP Right Grant
- 2011-11-02 KR KR1020187036509A patent/KR102049223B1/ko active Active
- 2011-11-02 HR HRP20161141TT patent/HRP20161141T1/hr unknown
- 2011-11-02 EA EA201300530A patent/EA030436B1/ru active Protection Beyond IP Right Term
- 2011-11-02 SG SG2013031745A patent/SG190006A1/en unknown
- 2011-11-02 SG SG10201604605VA patent/SG10201604605VA/en unknown
- 2011-11-02 EP EP11781949.0A patent/EP2635601B1/en active Active
- 2011-11-02 PL PL11781949T patent/PL2635601T3/pl unknown
- 2011-11-02 LT LTEP11781949.0T patent/LT2635601T/lt unknown
- 2011-11-02 HU HUE11781949A patent/HUE030916T2/en unknown
- 2011-11-02 KR KR1020137011474A patent/KR101931591B1/ko active Active
- 2011-11-02 GE GEAP201113106A patent/GEP201706733B/en unknown
- 2011-11-03 AR ARP110104094A patent/AR083747A1/es active IP Right Grant
- 2011-11-03 TW TW105114183A patent/TWI653242B/zh active
- 2011-11-03 TW TW100140204A patent/TWI545133B/zh active
- 2011-11-03 UY UY0001033703A patent/UY33703A/es active IP Right Grant
-
2012
- 2012-11-02 ME MEP-2016-176A patent/ME02499B/me unknown
-
2013
- 2013-04-09 IL IL225648A patent/IL225648A/en active Protection Beyond IP Right Term
- 2013-05-02 MA MA35866A patent/MA34641B1/fr unknown
- 2013-05-24 CO CO13128280A patent/CO6801628A2/es active IP Right Grant
- 2013-05-30 EC ECSP13012649 patent/ECSP13012649A/es unknown
-
2014
- 2014-06-12 US US14/302,986 patent/US9441036B2/en active Active
-
2016
- 2016-02-29 IL IL244335A patent/IL244335A/en active Protection Beyond IP Right Term
- 2016-08-04 US US15/228,254 patent/US10202448B2/en active Active
- 2016-09-13 CY CY20161100899T patent/CY1118014T1/el unknown
- 2016-12-16 AU AU2016273970A patent/AU2016273970B2/en active Active
-
2017
- 2017-01-13 JP JP2017003955A patent/JP6445596B2/ja active Active
-
2018
- 2018-09-24 AU AU2018236692A patent/AU2018236692C1/en active Active
- 2018-11-29 JP JP2018223469A patent/JP6758361B2/ja active Active
-
2019
- 2019-01-25 US US16/257,463 patent/US20190144534A1/en not_active Abandoned
- 2019-10-14 LU LU00132C patent/LUC00132I2/fr unknown
- 2019-10-14 HU HUS1900048 patent/HUS1900048I1/hu unknown
- 2019-10-15 LT LTPA2019518C patent/LTC2635601I2/lt unknown
- 2019-10-16 NL NL301013C patent/NL301013I2/nl unknown
- 2019-10-17 NO NO2019038C patent/NO2019038I1/no unknown
- 2019-10-17 CY CY2019040C patent/CY2019040I2/el unknown
-
2020
- 2020-10-09 US US17/066,994 patent/US20210198355A1/en not_active Abandoned
-
2024
- 2024-03-14 US US18/605,420 patent/US20250101093A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02499B (me) | Anti-il- 23-antitijela | |
| JP2014500009A5 (me) | ||
| HRP20191835T1 (hr) | Protutijela anti-il-36r | |
| HRP20201341T1 (hr) | Proteini za vezivanje na antigen st2 | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| HRP20130228T1 (hr) | Antitijela s visokim afinitetom za receptor humanog il 6 | |
| FI3353210T3 (fi) | Tigit-vasta-aineita ja käyttömenetelmiä | |
| JO3375B1 (ar) | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) | |
| JP2016520619A5 (me) | ||
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| HRP20160131T1 (hr) | Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba | |
| HRP20180320T1 (hr) | Protutijela koja vežu il-4 i/ili il-13 i njihova uporaba | |
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| SI2195023T1 (en) | Humanized anti-CXCR5 antibodies, their derivatives and their uses | |
| HRP20201633T1 (hr) | Protutijela koja se vežu na il-23 | |
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| JP2017184723A5 (me) | ||
| RU2016115866A (ru) | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи | |
| HRP20200174T1 (hr) | Antitijela antigena 2 anti-krvne dendritične stanice i njihova uporaba | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20250195T1 (hr) | Anti-fcrn antitijela | |
| HRP20192076T1 (hr) | Anti-il-17a protutijela i njihova uporaba u liječenju autoimunih i upalnih poremećaja | |
| HRP20240774T1 (hr) | Anti-il-33 antitijela i njihove upotrebe | |
| HRP20241528T1 (hr) | Monoklonsko protutijelo protiv interleukina-31 |